Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

Leukemia

Volumn 27, Issue 4, 2013, Pages 914-924

  Mustjoki, S ^a   Auvinen, K ^b   Kreutzman, A ^a   Rousselot, P ^c   Hernesniemi, S ^a   Melo, T ^d   Lahesmaa Korpinen, A M ^a   Hautaniemi, S ^a   Bouchet, S ^e   Molimard, M ^e   Smykla, R ^f   Lee, F Y ^f   Vakkila, J ^a   Jalkanen, S ^b,g   Salmi, M ^b,g   Porkka, K ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c CENTRE HOSPITALIER DE VERSAILLES   (France)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f BRISTOL MYERS SQUIBB   (United States)

^g UNIVERSITY OF TURKU   (Finland)

Author keywords

CML; dasatinib; immune activation; lymphocyte; mobilization

Indexed keywords

BASIC HELIX LOOP HELIX FAMILY E41; BOSUTINIB; CD19 ANTIGEN; COMPLEMENT COMPONENT C1Q; CXCL11 CHEMOKINE; CYCLIN DEPENDENT KINASE 14; DASATINIB; DEHYDROGENASE/REDUCTASE 9; DEOXYRIBONUCLEASE I LIKE 3; EARLY B CELL FACTOR 1; FC RECEPTOR LIKE 5; GLIAL CELL DERIVED NEUROTROPHIC FACTOR; GSG1 LIKE PROTEIN; HEAT SHOCK 70 KDA PROTEIN 12A; HLA COMPLEX 23; IMATINIB; IMMUNOGLOBULIN HEAVY CONSTANT ALPHA 2; IMMUNOGLOBULIN HEAVY CONSTANT GAMMA 1; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; METABOTROPIC RECEPTOR 4; NILOTINIB; OXYSTEROL BINDING PROTEIN LIKE 10; POU CLASS 2 ASSOCIATING FACTOR 1; PROTEIN; PUTATIVE UNCHARACTERIZED PROTEIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 2B1; TOLL LIKE RECEPTOR 10; TUMOR NECROSIS FACTOR RECEPTOR 13B; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; B LYMPHOCYTE; BASOPHIL; CANCER PATIENT; CELL FUNCTION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOTHELIUM CELL; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; LEUKOCYTE; LEUKOCYTE MOBILIZATION; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOSIS; MALE; MOLECULAR DYNAMICS; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL COUNT; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE; THROMBOCYTE COUNT; TREATMENT WITHDRAWAL;

ADULT; ANTINEOPLASTIC AGENTS; CYTOKINES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; K562 CELLS; MALE; PYRIMIDINES; T-LYMPHOCYTES, CYTOTOXIC; THIAZOLES;

EID: 84876139192     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.348     Document Type: Article

References (50)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
2. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
3. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
4. le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R et al. Nilotinib in patients with Ph\+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012; 26: 1189-1194.
5. Shami PJ, Deininger M. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 2012; 26: 214-224.
6. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551.
7. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.
8. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200-1206.
9. Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011; 25: 7-22.
10. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055-4063.
11. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104: 13283-13288.
12. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25: 1035-1044.
13. Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1698-1707.
14. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010; 116: 772-782.
15. Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L et al. Expansion of highly differentiated CD8(\+) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011; 25: 1587-1597.
16. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398-1405.
17. Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010; 91: 799-807.
18. Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011; 52: 668-679.
19. Valent JN, Schiffer CA. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leuk Res 2011; 35: e1-e3.
20. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of chronic myeloid leukemia patients at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85: 387-398.
21. Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009; 94: 135-139.
22. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008; 112: 1005-1012.
23. Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solidphase extraction and ultra performance LC/MS-MS. Clin Chim Acta 2011; 412: 1060-1067.
24. Ovaska K, Laakso M, Haapa-Paananen S, Louhimo R, Chen P, Aittomaki V et al. Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. Genome Med 2010; 2: 65.
25. Koskinen K, Vainio PJ, Smith DJ, Pihlavisto M, Yla-Herttuala S, Jalkanen S et al. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 2004; 103: 3388-3395.
26. Salmi M, Koskinen K, Henttinen T, Elima K, Jalkanen S. CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium. Blood 2004; 104: 3849-3857.
27. Palani S, Maksimow M, Miiluniemi M, Auvinen K, Jalkanen S, Salmi M. Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages. Eur J Immunol 2011; 41: 2052-2063.
28. Mustjoki S, Hernesniemi S, Rauhala A, Kahkonen M, Almqvist A, Lundan T et al. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica 2009; 94: 1469-1471.
29. Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006; 12: 7180-7186.
30. Lee SJ, Jung CW, Kim DY, Lee KH, Sohn SK, Kwak JY et al. Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. Am J Hematol 2011; 86: 346-350.
31. Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127: 330-339.
32. Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 2010; 24: 896-900.
33. Salih J, Hilpert J, Placke T, Grunebach F, Steinle A, Salih HR et al. The BCR/ABLinhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 2010; 127: 2119-2128.
34. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17: 1094-1100.
35. Yang Y, Liu C, Peng W, Lizee G, Overwijk WW, Liu Y et al. Anti-tumor T cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 2012; 120: 4533-4543.
36. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010; 116: 377-386.
37. Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011; 11: 30.
38. Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908-3914.
39. Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L et al. Efficacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22: 2176-2183.
40. Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol 2004; 172: 2011-2015.
41. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1039-1045.
42. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1046-1051.
43. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002; 3: 475-486.
44. Poliakov A, Cotrina M, Wilkinson DG. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell 2004; 7: 465-480.
45. Sharfe N, Nikolic M, Cimpeon L, Van De Kratts A, Freywald A, Roifman CM. EphA and ephrin-A proteins regulate integrin-mediated T lymphocyte interactions. Mol Immunol 2008; 45: 1208-1220.
46. Gleeson M, Bishop NC. The T cell and NK cell immune response to exercise. Ann Transplant 2005; 10: 43-48.
47. Turner JE, Aldred S, Witard OC, Drayson MT, Moss PM, Bosch JA. Latent cytomegalovirus infection amplifies CD8 T-lymphocyte mobilisation and egress in response to exercise. Brain Behav Immun 2010; 24: 1362-1370.
48. Schedlowski M, Hosch W, Oberbeck R, Benschop RJ, Jacobs R, Raab HR et al. Catecholamines modulate human NK cell circulation and function via spleenindependent beta 2-adrenergic mechanisms. J Immunol 1996; 156: 93-99.
49. Dimitrov S, Lange T, Born J. Selective mobilization of cytotoxic leukocytes by epinephrine. J Immunol 2010; 184: 503-511.
50. Fan G, Shumay E, Malbon CC, Wang H. c-Src tyrosine kinase binds the beta 2-adrenergic receptor via phospho-Tyr-350, phosphorylates G-protein-linked receptor kinase 2, and mediates agonist-induced receptor desensitization. J Biol Chem 2001; 276: 13240-13247.